09:15 AM EDT, 05/11/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our target to $84 from $98, based on 16.9x our 2027 EPS estimate, below GMED's five-year average forward P/E multiple. We raise our 2026 EPS view to $4.72 from $4.39 and our 2027 EPS forecast to $4.98 from $4.78. GMED reported a strong start to 2026, with first-quarter results significantly exceeding expectations on both revenue and earnings. Total revenue grew 27% Y/Y to $759.9M, while adjusted EPS surged 64.7% Y/Y to a record $1.12. The performance was led by robust, double-digit growth in the core Globus business, particularly in U.S. Spine, which has now grown over 10% for three consecutive quarters. However, the positive results were partially offset by the revenue decline in the recently acquired Nevro business as it undergoes strategic restructuring. Management attributed this to structural changes in the sales and marketing organization, but the CFO acknowledged that the performance would probably get a little bit worse before it gets better, highlighting some execution risk in the near term.